Avanos Medical, Inc. (AVNS) is a leading global medical technology company that is dedicated to challenging the status quo in health care, pursuing innovations that better patients' lives, and reducing healthcare costs by enabling the shift from invasive to non-invasive procedures. The company’s mission is to deliver clinically superior breakthrough solutions that will help patients around the world get back to living their lives, while helping healthcare professionals provide better care to more people at a lower cost. AVNS's portfolio of products focuses on respiratory and digestive health, along with surgical and interventional pain management.
Established in 2018 as a spin-off from Kimberly-Clark Corporation's health care division, Avanos has strived to provide better care at a lower cost by creating cutting-edge health devices that take a different approach to patient comfort and healing. The company is headquartered in Alpharetta, Georgia, and operates around the globe.
Avanos Medical, Inc operates through two segments - Chronic Care and Pain Management. The Chronic Care segment provides enteral feeding products, including enteral feeding tubes, strength-feeding devices, enteral nutrition safety systems, and gastric residuals measurement systems. In the pain management segment, AVNS's portfolio involves a wide range of devices and products such as radiofrequency ablation technology systems, nerve block needles, and catheter sets.
The enterprise sets high standards for quality, safety, and performance in healthcare. Avanos has been driven by patient-focused innovation. It uses clinical trials to validate the safety and efficacy of its products and technologies.
From a financial perspective, Avanos is a publicly listed company. Its shares are traded on the New York Stock Exchange (NYSE) under the ticker “AVNS”.
Commitment to social responsibility is also integral to Avanos's culture. It strategically contributes to causes around the world including humanitarian aid for disasters, surgical missions to third-world countries, and support for science, technology, engineering, math (STEM) education. Additionally, its commitment towards environment-friendly initiatives is reflected in its sustainability plan.
Avanos's innovative approach has propelled them to the forefront of their industry as they continue to challenge traditional healthcare methods. The company's strategy and leadership have maintained a clear focus on transforming Avanos into a leading medical device company that delivers the best-in-class growth and returns to its investors, all while implementing solutions that improve patient outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
FNY Investment Advisers LLC has acquired a new stake in Avanos Medical, Inc. (NYSE:AVNS), purchasing 103,500 shares valued at approximately $2.575 million, which now represents 0.9% of FNY’s holdings and 0.22% of Avanos Medical. Other institutional investors have also adjusted their positions in AVNS. Despite the stock opening near its 52-week high, analyst sentiment remains cautious with a consensus "Reduce" rating, although the company recently beat earnings expectations.
Latham & Watkins LLP advised the financing sources for American Industrial Partners' (AIP) acquisition of Avanos Medical, Inc. for approximately US$1.272 billion. The transaction involved a large legal team from Latham, providing expertise across various areas including capital markets, banking, executive compensation, data transactions, healthcare, environmental, and tax matters. This marks a significant deal for AIP, an industrials investor, in expanding its portfolio.